Jpmorgan Chase & CO Avidity Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 893,474 shares of RNA stock, worth $24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

893,474

Previous 967,903 7.69%

Holding current value

$24 Million

Previous $8.76 Million 160.32%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$9.16 - $25.52 $681,769 - $1.9 Million	-74,429 Reduced 7.69%	893,474 $22.8 Million
Q4 2023 Feb 12, 2024	SELL	$4.87 - $9.37 $13,631 - $26,226	-2,799 Reduced 0.29%	967,903 $8.76 Million
Q3 2023 Nov 14, 2023	BUY	$6.3 - $11.35 $2.65 Million - $4.77 Million	420,695 Added 76.49%	970,702 $6.19 Million
Q2 2023 Aug 11, 2023	SELL	$10.62 - $17.34 $31,615 - $51,621	-2,977 Reduced 0.54%	550,007 $6.1 Million
Q1 2023 May 18, 2023	BUY	$15.35 - $25.65 $1.27 Million - $2.12 Million	82,550 Added 17.55%	552,984 $8.49 Million

Q1 2023 May 11, 2023	BUY	$15.35 - $25.65 $5.3 Million - $8.86 Million	345,516 Added 276.59%	470,434 $7.22 Million
Q4 2022 Feb 13, 2023	BUY	$10.06 - $22.66 $138,797 - $312,640	13,797 Added 12.42%	124,918 $2.77 Million
Q3 2022 Nov 14, 2022	SELL	$15.46 - $23.43 $239,027 - $362,251	-15,461 Reduced 12.21%	111,121 $1.81 Million
Q2 2022 Aug 11, 2022	BUY	$11.18 - $20.5 $284,721 - $522,073	25,467 Added 25.19%	126,582 $1.84 Million
Q1 2022 May 11, 2022	SELL	$14.2 - $23.78 $145,635 - $243,887	-10,256 Reduced 9.21%	101,115 $1.87 Million
Q4 2021 Feb 10, 2022	BUY	$20.4 - $28.66 $1.72 Million - $2.42 Million	84,266 Added 310.89%	111,371 $2.65 Million
Q3 2021 Nov 12, 2021	BUY	$18.16 - $25.21 $492,226 - $683,317	27,105 New	27,105 $668,000

Others Institutions Holding RNA

# of Institutions

164

Shares Held

71.6M

Call Options Held

182K

Put Options Held

55K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.4B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Avidity Biosciences, Inc. Transaction History